Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The "COSMOS"-Study (Copeptin in Osmoregulation and Stress Assessment)

This study has been completed.
Information provided by:
University Hospital, Basel, Switzerland Identifier:
First received: October 20, 2006
Last updated: September 22, 2008
Last verified: September 2008

Sodium imbalance is common and an adverse prognostic factor in hospitalized patients. However, identifying the causes of sodium imbalance is challenging in clinical practice. Levels of antidiuretic hormone (ADH) are elevated in patients with stroke correlating with disease severity and stress level; however, its measurement is cumbersome. ADH is derived from a larger precursor peptide along with Copeptin, which is a more stable peptide directly mirroring the production of ADH. Copeptin can be assayed readily in plasma. Early prognostic factors to predict in-hospital mortality and medium/long-term outcome in critically ill neurological patients, are helpful to guide and tailor early decisions on treatment, discharge from the intensive care unit and application of interventions to prevent deterioration of neurological functions.

We hypothesize that copeptin will improve the diagnostic accuracy to diagnose sodium imbalances as compared to routinely used markers Furthermore, we hypothesize that Copeptin will be a reliable prognostic tool, dependent or independent of sodium imbalance, to predict short-term (i.e. in-hospital) and medium-term (i.e. 3 months) clinical outcome in stroke patients.

Transient Ischemic Attack

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Copeptin as a Novel Diagnostic and Prognostic Marker in the Management of Neurological and Neurosurgical Patients With Sodium Imbalance The "COSMOS"-Study (Copeptin in Osmoregulation and Stress Assessment)

Resource links provided by NLM:

Further study details as provided by University Hospital, Basel, Switzerland:

Biospecimen Retention:   Samples Without DNA

bood sampling

Enrollment: 469
Study Start Date: November 2006
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
  Show Detailed Description


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

All consecutive patients who are admitted to the emergency department with an ischemic or hemorrhagic stroke or transient ischemic attach (TIA) according to the World Health organization criteria [37] with symptom onset within the last 3 days.


Inclusion Criteria:

  1. All consecutive patients who are admitted to the emergency department with an ischemic or hemorrhagic stroke or transient ischemic attach (TIA) according to the World Health organization criteria [37] with symptom onset within the last 3 days.
  2. All consecutive patients who undergo intracranial surgery due to

    • pituitary tumors
    • intracerebral hemorrhage (ICH)
    • subarachnoidal hemorrhage (SAH)
    • chronic subdural hematoma
    • head trauma with contusion cerebri
    • intracranial abcesses

Exclusion Criteria:

  • Patients without informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00390962

University Hospital Basel
Basel, BS, Switzerland, 4051
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Study Chair: Beat Mueller, Prof University Hospital, Basel, Switzerland
  More Information

No publications provided by University Hospital, Basel, Switzerland

Additional publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00390962     History of Changes
Other Study ID Numbers: EKBB 157/06
Study First Received: October 20, 2006
Last Updated: September 22, 2008
Health Authority: Switzerland: Ethikkommission

Keywords provided by University Hospital, Basel, Switzerland:
diabetes insipidus
risk factors
Neurological patients with ischemic and hemorrhagic stroke and patients undergoing intracranial surgery.

Additional relevant MeSH terms:
Ischemic Attack, Transient
Brain Diseases
Brain Ischemia
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Nervous System Diseases
Vascular Diseases processed this record on March 03, 2015